Желчно-каменная болезнь в XXI веке: лечение или профилактика?

1. Sandler RS, Everhart JE, Donowitz M et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122 (5): 1500–11.
2. Болезни печени и желчевыводящих путей: Руководство для врачей. Под. ред. В.Т.Ивашкина. М.: М-Вести, 2002.
3. Sun H, Tang H, Jiang S et al. Gender and metabolic differences of gallstone diseases.World J Gastroenterol 2009; 15 (15): 1886–91.
4. Schirmer BD, Edlich RF, Winters KL. Cholelithiasis and Cholecystitis. J Long Term Eff Med Implants 1990; 15: 3.
5. Dowling RH. Review: pathogenesis of gallstones. Aliment Pharmacol Ther 2000; 14 (Suppl.): 39–47.
6. Лейшнер У. Практическое руководство по заболеваниям желчных путей. М.: ГЭОТАР-МЕД, 2001.
7. Chiang JY, Kimmel R, Stroup D. Gene. Regulation of cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha). 2001; 10; 262 (1–2): 257–65.
8. Twisk J, Hoekman MF, Mager WH et al. Heterogeneous expression of cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase genes in the rat liver lobulus. J Clin Invest 1995; 95: 1235–43.
9. Groothuis GM, Hardonk MJ, Keulemans KP et al. Autoradiographic and kinetic demonstration of acinar heterogeneity of taurocholate transport. Am J Physiol GastrointestLiver Physiol 1982; 243: G455–62.
10. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003; 72: 137–74.
11. Chiang JY. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J Hepatol 2004; 40: 539–51.
12. Makishima M, Okamoto AY, Repa JJ et al. Identification of a nuclear receptor for bile acids. Science 284: 1362–5.
13. Wang H, Chen J, Hollister K et al. Endogenous receptor FXR/BAR. Mol Cell 3: 543–553.
14. Lefebvre P, Cariou B, Lien F et al. Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation. Physiol Rev 2009; 89: 147–91.
15. Trauner M, Claudel T, Fickert P et al. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis 2010; 28 (1): 220–4.
16. Watanabe M, Houten SM, Mataki C et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439: 484–9.
17. Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci 2009; 30 (11): 570–80.
18. Ke Ma, Pradip K. Saha et al. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006; 116: 1102–9.
19. Chiang JYL. Bile Acid Regulation of Hepatic Physiology III. Bile acids and nuclear receptors. Am J Physiol Gastrointest Liver Physiol 2003; 284: G349–56.
20. Mendez-Sanchez N, Chavez-Tapia NC, Motola-Kuba D et al. Metabolic syndrome as a risk factor for gallstone disease World J Gastroenterol 2005; 11 (11): 1653–7.
21. Liu CM, Tung TH, Liu JH et al. A communitybased epidemiologic study on gallstone disease among type 2 diabetics in Kinmen, Taiwan. Dig Dis 2004; 22: 87–91.
22. De Santis A, Attili AF, Ginanni Corradini S et al. Gallstones and diabetes: a case-control study in a free-livingpopulation sample. Hepatology 1997; 25: 787–90.
23. Kim JM, Lee HL, Moon W et al. Association between insulin, insulin resistance, and gallstone disease in Korean general population. Korean J Gastroenterol 2007; 50 (3): 183–7.
24. Mndez-Snchez N, Bahena-Aponte J, Chvez-Tapia NC et al. Strong association between gallstones and cardiovascular disease. Am J Gastroenterol 2005; 100 (4): 827–30.
25. Chen CH, Huang MH, Yang JC et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol 2006; 40 (8): 745–52.
26. Mudipalli A. Indian J Med Res 2007; 126: 518–27.
27. Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999; 159 (22): 2647–58.
28. Wagner M, Trauner M. Transcriptional regulation of hepatobiliary transport systems in health and disease: implications for a rationale approach to the treatment of intrahepatic cholestasis. Ann Hepatol 2005; 4 (2): 77–99.
29. Gilat T, Leikin-Frenkel A, Goldiner I et al. Dissolution of Cholesterol Gallstones in Mice by the Oral Administration of a Fatty Acid Bile Acid Conjugate. Hepatology 2002; 35 (3): 597–600.
30. Вовк Е.И. Выбор препаратов панкреатина для лечения нарушений пищеварения у больных хроническим панкреатитом и желчнокаменной болезнью. www.pharmateca.ru